- Home
- RMCF vs KZIA Comparison
RMCF vs KZIA Comparison
Compare RMCF & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- KZIA
- Stock Information
- Founded
- RMCF 1981
- KZIA 1994
- Country
- RMCF United States
- KZIA Australia
- Employees
- RMCF N/A
- KZIA N/A
- Industry
- RMCF Specialty Foods
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- KZIA Health Care
- Exchange
- RMCF Nasdaq
- KZIA Nasdaq
- Market Cap
- RMCF 14.3M
- KZIA 12.6M
- IPO Year
- RMCF N/A
- KZIA 1999
- Fundamental
- Price
- RMCF $2.55
- KZIA $5.48
- Analyst Decision
- RMCF
- KZIA Strong Buy
- Analyst Count
- RMCF 0
- KZIA 1
- Target Price
- RMCF N/A
- KZIA $20.00
- AVG Volume (30 Days)
- RMCF 94.5K
- KZIA 148.4K
- Earning Date
- RMCF 01-08-2025
- KZIA 11-19-2024
- Dividend Yield
- RMCF N/A
- KZIA N/A
- EPS Growth
- RMCF N/A
- KZIA N/A
- EPS
- RMCF N/A
- KZIA N/A
- Revenue
- RMCF $27,743,687.00
- KZIA $382.00
- Revenue This Year
- RMCF N/A
- KZIA $4,053,954.00
- Revenue Next Year
- RMCF N/A
- KZIA N/A
- P/E Ratio
- RMCF N/A
- KZIA N/A
- Revenue Growth
- RMCF N/A
- KZIA N/A
- 52 Week Low
- RMCF $1.50
- KZIA $1.90
- 52 Week High
- RMCF $5.15
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- RMCF 54.92
- KZIA 51.94
- Support Level
- RMCF $2.42
- KZIA $5.51
- Resistance Level
- RMCF $2.70
- KZIA $6.88
- Average True Range (ATR)
- RMCF 0.24
- KZIA 0.78
- MACD
- RMCF -0.04
- KZIA -0.05
- Stochastic Oscillator
- RMCF 17.76
- KZIA 33.93
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.